GlassScriptPhysician profile
Lara A Match
NPI 1245683267
$1,943.82
in general payments reported to CMS, 2019-2025
16 companies · $613 in 2025
The $613 reported for 2025 was more than what 82% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $203 · 2020: $130 · 2021: $190 · 2022: $233 · 2023: $247 · 2024: $328 · 2025: $613.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,188.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,187.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $458.32 | 2020-2025 | Cequa |
| Biotissue Holdings INC. | $379.44 | 2019-2025 | |
| Alcon Vision LLC | $179.80 | 2019-2025 | Precision 1, Total30 |
| Thea Pharma INC. | $145.98 | 2025 | Iyuzeh |
| Genzyme Corporation | $140.35 | 2019-2025 | |
| Lkc Technologies, INC. | $95.80 | 2024 | |
| Bausch & Lomb Americas INC. | $90.57 | 2025 | Alden Scleral Zenlens |
| Oyster Point Pharma, INC. | $88.65 | 2022-2023 | Tyrvaya |
| Shire North American Group INC | $69.19 | 2019 | |
| Coopervision INC. | $63.92 | 2020-2025 | Clariti Contact Lens |
| Eyevance Pharmaceuticals LLC | $59.44 | 2022 | |
| Johnson & Johnson Vision Care, INC. | $47.54 | 2021-2022 | |
| Sight Sciences, INC. | $45.82 | 2020 | |
| Abbvie INC. | $28.35 | 2024 | |
| Allergan, INC. | $26.67 | 2021 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Plexus Optix, INC. | $23.98 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lara Match listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.